Women’s health startup Genneve lands $4M to grow telemedicine service for menopause
Summary
Genneve, a Seattle startup that runs a telemedicine service for women experiencing menopause, landed a $4 million seed round led by BlueRun Ventures. CEO Jill Angelo characterizes Genneve’s target market as “women kicking off the second half of life, starting with menopause.” Telemedicine was a bit of a pivot for the three-year-old startup, which first launched by selling personal lubricants and information for menopausal women. Nearly half of all U.S. counties lack a single OB-GYN provider, and the shortfall is expected to reach 8,000 in 2020, according to the American College of Obstetricians and Gynecologists. “Genneve is addressing a large and unserved market,” BlueRun Ventures managing partner Cheryl Cheng said in an email. Genneve’s competition includes Rory, a sister company to erectile dysfunction startup Roman, which offers over-the-counter products for menopause as well as prescription treatments, which can be given to patients after an online doctor’s visit.